<a href="https://laohu8.com/S/AZTR">Azitra Inc</a>. Announces Promising Safety Results for ATR-12 Phase 1b Clinical Trial in Netherton Syndrome and Initiates ATR-04 Phase 1/2 Trial for EGFRi-Associated Dermal Toxicity
Azitra, Inc., a clinical stage biopharmaceutical company specializing in precision dermatology, has announced new developments in its clinical trials pipeline. The company recently reported promising safety results from its Phase 1b clinical trial of the ATR-12 program for Netherton syndrome. Additionally, Azitra has initiated a Phase 1/2 clinical trial for the ATR-04 program, targeting EGFR inhibitor-associated dermal toxicity in adults. The design of the ATR-04 trial was previously presented at the 2025 American Society of Clinical Oncology Annual Meeting. Further updates and progress on these programs will be presented by Cofounder and Chief Operating Officer, Travis Whitfill, Ph.D., MPH, during a virtual presentation at the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY64956) on September 04, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。